- AREV NanoTec Brands (AREV) is utilizing its proprietary extraction technologies to identify broad-spectrum antiviral agents from medicinal photochemistry source
- These include bioactive compounds sourced from Moringa oleifera and Moringa ovalifolia
- AREV’s current efforts to secure the antiviral characteristics of COVID-19’s Mpro remains the important drug target against COVID-19 infection
- More than 2000 plant species have the potential for being used as medicinal plants
- It has been estimated that plant-derived drugs constitute as much as 25 per cent of the total therapeutics
- AREV NanoTech Brands (AREV) is down 11.54 per cent and is trading at C$0.34 at 2:43 pm EST
AREV NanoTec Brands (AREV) utilizes its proprietary extraction technologies to identify broad-spectrum antiviral agents from medicinal photochemistry sources.
These include bioactive compounds sourced from Moringa oleifera and Moringa ovalifolia, identified in peer-reviewed publications as presenting a wide range of antiviral activity and may demonstrate a high affinity with viral protease inhibition.
Mike Withrow, CEO of AREV Nanotec, responded by mentioning AREVS collaboration with university centers.
“Regarding the COVID-19 pandemic, AREV is pursuing collaborations with several world-renowned University centers to facilitate advanced extraction of potential antiviral phytochemicals from medicinal plant libraries for screening specific small molecules that may be used to develop drugs against COVID-19 and other pandemic viral pathogens.”
“The work AREV already is doing for raw material sourcing in the natural products industry has allowed the evolution of corporate expertise to now become relevant for advancing discoveries in medicinal photochemistry,” added Withrow.
AREV’s current efforts to secure the antiviral characteristics of COVID-19’s Mpro remains the important drug target against COVID-19 infection.
This will involve grant solicitation from funding sources for pre-clinical discovery, including NSF’s Rapid Response Research program to mobilize funding for high-priority projects.
More than 2000 plant species have the potential for being used as medicinal plants.
It has been estimated that plant-derived drugs constitute as much as 25 per cent of the total therapeutics.
Simultaneously, in fast-developing countries such as India and China, the contribution is as much as 80 per cent.
AREV is not making any express or implied claims that it can eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus) at this time.
AREV has issued 350 thousand stock options to Directors, Officers and Consultants of AREV at C$0.39 for five years from the given date.
AREV is an early-stage publicly traded life science development enterprise focused on the phytomedicinal extraction of novel therapeutic approaches to infectious diseases and subsequent comorbidities.
AREV NanoTech Brands (AREV) is down 11.54 per cent and is trading at C$0.34 at 2:43 pm EST.
